Facilitators and Barriers to Cancer Treatment Among Texas Residents

Not Applicable

Not yet recruiting

• Conditions: Cancer

• Registration Number: NCT07105046
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

This trial uses semi-structured interviews and focus groups to determine facilitators and barriers of receiving timely cancer treatment among multiple cancers, across multiple insurance types, throughout Texas

Detailed Description

Primary Objectives:

Aim 1: To comprehensively assess barriers to and facilitators of receiving timely cancer treatment, via in-depth telephone interviews among a purposive sample of Texas patients with Stage I-IV breast, colorectal, lung, and prostate cancer and diverse backgrounds.

Aim 2: To generate consensus on barriers and facilitators, as well as their relative importance, via focus groups, among carefully selected Texas patients with Stage I-IV breast, colorectal, lung and prostate cancer and diverse backgrounds,

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-29
• Study First Submitted QC: 2025-07-29
• Last Update Submitted: 2025-07-29
• Study First Posted: 2025-08-05
• Last Update Posted: 2025-08-05
• Study Start: 2026-01-31
• Primary Completion: 2026-12-31
• Study Completion: 2028-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Aims 1 and 2

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

• Verbal consent will be obtained
• Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
• Males and females; Age ≥ 18 years old
• Documented diagnosis of breast, colorectal, lung, and prostate cancer patients, stage I-IV
• Either English or Spanish-speaking

Exclusion Criteria

Aims 1 and 2

An individual who meets any of the following criteria will be excluded from participation in this study:

• Patients who are cognitively impaired
• Pregnant women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
1. Safety and Adverse Events (AEs)	Through study completion; an average of 1 year	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Trial Locations

Locations (1)

The University of Texas M. D. Anderson Cancer Center; 🇺🇸 Houston, Texas, United States